Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir | Zendy

Alicia GutiérrezValencia | Zendy; Rosa Ruiz-Valderas | Zendy; Almudena Torres-Cornejo | Zendy; Pompeyo Viciana | Zendy; Núria Espinosa | Zendy; J R Castillo-Ferrando | Zendy; Luís F. LópezCortés | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir

Author(s) -

Alicia GutiérrezValencia,

Rosa Ruiz-Valderas,

Almudena Torres-Cornejo,

Pompeyo Viciana,

Núria Espinosa,

J R Castillo-Ferrando,

Luís F. LópezCortés

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit693

Subject(s) - cmin , medicine , ritonavir , cmax , atazanavir , pharmacokinetics , telaprevir , pharmacology , regimen , adverse effect , ribavirin , viral load , gastroenterology , virology , hepatitis c virus , human immunodeficiency virus (hiv) , antiretroviral therapy , virus

Detrimental bidirectional pharmacokinetic interactions have been observed when telaprevir (TVR) and ritonavir (RTV)-boosted human immunodeficiency virus (HIV) protease inhibitors are coadministered in healthy volunteers. Our aim was to evaluate the role of RTV in the bidirectional TVR and atazanavir (ATV) interactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research